Abstract
Traditionally, breast cancer (BC) is divided into different subtypes defined by immunohistochemistry (IHC) according to the expression of hormone receptors and overexpression/amplification of human epidermal growth factor receptor 2 (HER2), with crucial therapeutic implications. In the last few years, the definition of different BC molecular subgroups within the IHC-defined subtypes and the identification of the important role that molecular heterogeneity can play in tumor progression and treatment resistance have inspired the search for personalized therapeutic approaches. In this scenario, translational research represents a key strategy to apply knowledge from cancer biology to the clinical setting, through the study of all the tumors “omics”, including genomics, transcriptomics, proteomics, epigenomics, and metabolomics. Importantly, the introduction of new high-throughput technologies, such as next generation sequencing (NGS) for the study of cancer genome and transcriptome, greatly amplifies the potential and the applications of translational research in the oncology field. Moreover, the introduction of new experimental approaches, such as liquid biopsy, as well as new-concept clinical trials, such as biomarker-driven adaptive studies, may represent a turning point for BC translational research.
It is likely that translational research will have in the near future a significant impact on BC care, especially by giving us the possibility to dissect the complexity of tumor cell biology and develop new personalized treatment strategies.
Keywords: Breast cancer, translational research, liquid biopsy, personalized treatment, IHC, HER2.
Anti-Cancer Agents in Medicinal Chemistry
Title:The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?
Volume: 18 Issue: 6
Author(s): Giuseppe Buono*, Francesco Schettini, Francesco Perri*, Grazia Arpino, Roberto Bianco, Carmen Criscitiello, Sabino De Placido and Mario Giuliano
Affiliation:
- Medical Oncology and Surgery, University of Naples ,Italy
- San Giuseppe Moscati Hospital, Taranto,Italy
Keywords: Breast cancer, translational research, liquid biopsy, personalized treatment, IHC, HER2.
Abstract: Traditionally, breast cancer (BC) is divided into different subtypes defined by immunohistochemistry (IHC) according to the expression of hormone receptors and overexpression/amplification of human epidermal growth factor receptor 2 (HER2), with crucial therapeutic implications. In the last few years, the definition of different BC molecular subgroups within the IHC-defined subtypes and the identification of the important role that molecular heterogeneity can play in tumor progression and treatment resistance have inspired the search for personalized therapeutic approaches. In this scenario, translational research represents a key strategy to apply knowledge from cancer biology to the clinical setting, through the study of all the tumors “omics”, including genomics, transcriptomics, proteomics, epigenomics, and metabolomics. Importantly, the introduction of new high-throughput technologies, such as next generation sequencing (NGS) for the study of cancer genome and transcriptome, greatly amplifies the potential and the applications of translational research in the oncology field. Moreover, the introduction of new experimental approaches, such as liquid biopsy, as well as new-concept clinical trials, such as biomarker-driven adaptive studies, may represent a turning point for BC translational research.
It is likely that translational research will have in the near future a significant impact on BC care, especially by giving us the possibility to dissect the complexity of tumor cell biology and develop new personalized treatment strategies.
Export Options
About this article
Cite this article as:
Buono Giuseppe*, Schettini Francesco, Perri Francesco*, Arpino Grazia, Bianco Roberto, Criscitiello Carmen, De Placido Sabino and Giuliano Mario, The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (6) . https://dx.doi.org/10.2174/1871520617666171103105247
DOI https://dx.doi.org/10.2174/1871520617666171103105247 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor metastasis ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
Metalloenzymes and Cancer: Μetalloenzyme Ιnhibitors and Artificial Metalloenzymes as anti-cancer agents
Metalloenzymes are enzymes containing metal ions, which are directly bound to the enzyme and play a role in promoting catalysis. About one-third of all enzymes known so far are metalloenzymes [1]. Metalloenzymes are central to a wide range of essential biological activities, including nucleic acid modification, protein degradation, and many ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anionic Antimicrobial Peptides from Eukaryotic Organisms
Current Protein & Peptide Science Targeting Steroid Hormone Receptor Pathways in the Treatment of Hormone Dependent Cancers
Current Pharmaceutical Biotechnology Subject Index to Volume 3
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Expression Microarray Proteomics and the Search for Cancer Biomarkers
Current Genomics Quality Survival with Fertility after Gynaecological and other Cancers
Current Women`s Health Reviews Biospecies Capture and Detection at Low Concentration
Micro and Nanosystems Interview with Dr. Young-Ki Paik, President of the Human Proteome Organization (HUPO): Pharmacoproteomics and the Approaching Wave of “Proteomics Diagnostics”
Current Pharmacogenomics and Personalized Medicine LINE-1 Methylation is Associated with an Increased Risk of Ischemic Stroke in Men
Current Neurovascular Research Mechanisms and Drug Targets for Pancreatic Cancer Chemoprevention
Current Medicinal Chemistry Retroviral Gene Therapy: Safety Issues and Possible Solutions
Current Gene Therapy In Vitro Inhibitory Effect of Recombinant Human Calprotectin on Nalm6 Leukemia Cell Line
Anti-Cancer Agents in Medicinal Chemistry Cannabinoid Hyperemesis Syndrome
Current Drug Abuse Reviews Randomized Double-blind Placebo-controlled Trial of Celecoxib for the Prevention of Skin Toxicity in Patients Receiving Radiation Therapy for Breast Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current Management of Neonatal Soft-tissue Sarcomas and Benign Tumors with Local Aggressiveness
Current Pediatric Reviews Advanced Glycation End Products (AGEs), Glutathione and Breast Cancer: Factors, Mechanism and Therapeutic Interventions
Current Drug Metabolism Research Progress of PD 1/PD L1 Inhibitors in the Treatment of Urological Tumors
Current Cancer Drug Targets Erlotinib in Glioblastoma - Lost in Translation?
Anti-Cancer Agents in Medicinal Chemistry Exploring the Therapeutic Potential of Chalcones in Oncology: A Comprehensive Review
Current Bioactive Compounds Applications of Natural Compounds in the Photodynamic Therapy of Skin Cancer
Current Medicinal Chemistry Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy
Current Pharmaceutical Design